Trial Profile
Phase II Pilot Study With TMX 101 in Patients With Carcinoma In Situ (CIS) Bladder Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 May 2016
Price :
$35
*
At a glance
- Drugs Imiquimod (Primary)
- Indications Bladder cancer
- Focus Therapeutic Use
- Sponsors Telormedix
- 10 May 2016 Results presented at the 111th Annual Meeting of the American Urological Association
- 05 May 2016 Data will be presented at the American Urology Association 2016 Annual Meeting, according to an UroGen Pharma media release.
- 16 May 2014 Top-line results reported in a Telormedix media release.